Novel therapies not primarily dependent on the functioning of LDLR include lomitapide [38,46] and mipomersen [39,40,46,47], which decrease hepatic apolipoprotein B secretion, and evinacumab [48,49,50,51], directed at the angiopoietin like-3 protein (ANGPLT-3), which enhances clearance of highly atherogenic TLRs [52,53,54] and lowers the risk of ASCVD [55,56]. This evidence concerns the gene LDLR and atherosclerosis.